Intelligent Bio Solutions vs Lucid Diagnostics
INBS and LUCD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INBS and LUCD compare
Lucid Diagnostics is the larger company, worth 17 times as much as Intelligent Bio Solutions ($91.3M against $5.3M).
Intelligent Bio Solutions grew revenue faster over the last twelve months (36.5% versus 23.6% for Lucid Diagnostics).
Intelligent Bio Solutions keeps more of each dollar of sales as profit, with a net margin of −269% compared with −893% at Lucid Diagnostics.
Intelligent Bio Solutions scores higher on the StockData Score (8 against 7 for Lucid Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INBS | LUCD |
|---|---|---|
| Size and price | ||
| Market cap | $5.3M | $91.3M |
| Share price | $1.76 | $0.449 |
| Change, 1 year | −77.8% | −59.5% |
| Change, 5 years | −100.0% | −95.2% |
| Beta (5Y) | 1.97 | 1.04 |
| Employees | 14 | 82 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.2× (better) | 16.8× |
| P/B | 0.7× (better) | 15.4× |
| FCF yield | – | −56.8% |
| Fair value | $4.50 | $0.253 |
| Margin of safety | 60.9% (better) | −77.8% |
| Growth | ||
| Revenue growth (TTM) | 36.5% (better) | 23.6% |
| Revenue growth, 5Y average | 16.3% | – |
| Profitability | ||
| Gross margin | 50.9% (better) | −16.5% |
| Operating margin | −272% (better) | −942% |
| Net margin | −269% (better) | −893% |
| FCF margin | – | −953% |
| Return on equity | −216% (better) | −306% |
| Return on invested capital | −535% | – |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −187.7× (better) | −3011.9× |
| Current ratio | 1.98 (better) | 1.20 |
| Altman Z-score | −9.71 (better) | −19.24 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 6.0% | 30.2% |
| Held by insiders | 3.0% | 24.8% |
| Insider net buying, 12 months | – | $245K |
| Short interest, % of float | 2.2% | 9.8% |
Go deeper
- INBS stock overview
- INBS income statement
- INBS valuation and score
- LUCD stock overview
- LUCD income statement
- LUCD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.